Skip to main content


Fig. 2 | Cell Communication and Signaling

Fig. 2

From: Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma

Fig. 2

a Left panel, examples of whole spleens from isotype control (Ctrl) and anti-PD-L1 (αPD-L1) antibody treated LMP1/CD40-expressing mice; middle panel, mean and standard deviation of spleen weight; right panel, absolute numbers of spleen B cells. For the PD-L1 treatment, LMP1/CD40-expressing mice were injected every 4 days for three weeks with 200 μg anti-PD-L1 antibody in In VivoPure Dilution Buffer (clone 10F.9G2; Bio X cell; US). b Spleen B220 B-cell absolute numbers assessed by flow cytometry in Ctrl and αPD-L1 treated LMP1/CD40-expressing mice. c Absolute numbers assessed by flow cytometry of spleen B220 B-cells expressing CD80 and/or CD86 activation markers in LMP1/CD40-expressing mice after injection of isotope control (Ctrl) or anti-PD-L1 (αPD-L1) antibody. d Mean and standard deviation of flow cytometry percentages of BrdU positive B-cells after in vivo BrdU incorporation in Ctrl and αPD-L1 treated LMP1/CD40-expressing mice. Mice were injected intraperitoneally with 2 mg BrdU, 18 h before isolating cells. (e) Hematein eosin staining of 5 μm section of paraffin embedded spleen tissues with, as insert, the imprint May-Grunwald staining of the same spleen of Ctrl- (left panel) and αPD-L1- (right panel) LMP1/CD40-expressing mice. Statistical significance was determined by unpaired t-test (**P < 0.01; *P < 0.05)

Back to article page